These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 17428587

  • 1. Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates.
    Qian F, Wu Y, Muratova O, Zhou H, Dobrescu G, Duggan P, Lynn L, Song G, Zhang Y, Reiter K, MacDonald N, Narum DL, Long CA, Miller LH, Saul A, Mullen GE.
    Vaccine; 2007 May 16; 25(20):3923-33. PubMed ID: 17428587
    [Abstract] [Full Text] [Related]

  • 2. Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle.
    Shimp RL, Rowe C, Reiter K, Chen B, Nguyen V, Aebig J, Rausch KM, Kumar K, Wu Y, Jin AJ, Jones DS, Narum DL.
    Vaccine; 2013 Jun 19; 31(28):2954-62. PubMed ID: 23623858
    [Abstract] [Full Text] [Related]

  • 3. Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders.
    Qian F, Rausch KM, Muratova O, Zhou H, Song G, Diouf A, Lambert L, Narum DL, Wu Y, Saul A, Miller LH, Long CA, Mullen GE.
    Vaccine; 2008 May 12; 26(20):2521-7. PubMed ID: 18423804
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Accelerated and long term stability study of Pfs25-EPA conjugates adjuvanted with Alhydrogel®.
    Zhu D, Wu Y, McClellan H, Dai W, Rausch K, Jones D, Aebig J, Barnafo E, Butler B, Lambert L, Narum DL, Duffy PE.
    Vaccine; 2017 May 31; 35(24):3232-3238. PubMed ID: 28479180
    [Abstract] [Full Text] [Related]

  • 7. Immunization with a functional protein complex required for erythrocyte invasion protects against lethal malaria.
    Srinivasan P, Ekanem E, Diouf A, Tonkin ML, Miura K, Boulanger MJ, Long CA, Narum DL, Miller LH.
    Proc Natl Acad Sci U S A; 2014 Jul 15; 111(28):10311-6. PubMed ID: 24958881
    [Abstract] [Full Text] [Related]

  • 8. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
    Arakawa T, Komesu A, Otsuki H, Sattabongkot J, Udomsangpetch R, Matsumoto Y, Tsuji N, Wu Y, Torii M, Tsuboi T.
    Infect Immun; 2005 Nov 15; 73(11):7375-80. PubMed ID: 16239536
    [Abstract] [Full Text] [Related]

  • 9. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
    Sirima SB, Durier C, Kara L, Houard S, Gansane A, Loulergue P, Bahuaud M, Benhamouda N, Nebié I, Faber B, Remarque E, Launay O, AMA1-DiCo Study Group.
    Vaccine; 2017 Oct 27; 35(45):6218-6227. PubMed ID: 28947345
    [Abstract] [Full Text] [Related]

  • 10. Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology.
    Li Y, Leneghan DB, Miura K, Nikolaeva D, Brian IJ, Dicks MD, Fyfe AJ, Zakutansky SE, de Cassan S, Long CA, Draper SJ, Hill AV, Hill F, Biswas S.
    Sci Rep; 2016 Jan 08; 6():18848. PubMed ID: 26743316
    [Abstract] [Full Text] [Related]

  • 11. Maintaining immunogenicity of blood stage and sexual stage subunit malaria vaccines when formulated in combination.
    Parzych EM, Miura K, Long CA, Burns JM.
    PLoS One; 2020 Jan 08; 15(4):e0232355. PubMed ID: 32348377
    [Abstract] [Full Text] [Related]

  • 12. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.
    Kennedy MC, Wang J, Zhang Y, Miles AP, Chitsaz F, Saul A, Long CA, Miller LH, Stowers AW.
    Infect Immun; 2002 Dec 08; 70(12):6948-60. PubMed ID: 12438374
    [Abstract] [Full Text] [Related]

  • 13. Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice.
    Healy SA, Anderson C, Swihart BJ, Mwakingwe A, Gabriel EE, Decederfelt H, Hobbs CV, Rausch KM, Zhu D, Muratova O, Herrera R, Scaria PV, MacDonald NJ, Lambert LE, Zaidi I, Coelho CH, Renn JP, Wu Y, Narum DL, Duffy PE.
    J Clin Invest; 2021 Apr 01; 131(7):. PubMed ID: 33561016
    [Abstract] [Full Text] [Related]

  • 14. [Conjugation of Plasmodium falciparum Pfs25 to Pseudomonas aeruginosa ExoProtein A with different chemical linkers].
    Qian F.
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2011 Aug 01; 29(4):254-7. PubMed ID: 21972597
    [Abstract] [Full Text] [Related]

  • 15. Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines.
    Miao J, Li X, Liu Z, Xue C, Bujard H, Cui L.
    Vaccine; 2006 Sep 11; 24(37-39):6187-98. PubMed ID: 16806600
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection.
    Biswas S, Spencer AJ, Forbes EK, Gilbert SC, Holder AA, Hill AV, Draper SJ.
    J Immunol; 2012 May 15; 188(10):5041-53. PubMed ID: 22504652
    [Abstract] [Full Text] [Related]

  • 18. First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development.
    Salman M, St Michael F, Ali A, Jabbar A, Cairns C, Hayes AC, Rahman M, Iqbal M, Haque A, Cox AD.
    J Immunol Methods; 2017 Nov 15; 450():27-33. PubMed ID: 28735760
    [Abstract] [Full Text] [Related]

  • 19. Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230.
    MacDonald NJ, Nguyen V, Shimp R, Reiter K, Herrera R, Burkhardt M, Muratova O, Kumar K, Aebig J, Rausch K, Lambert L, Dawson N, Sattabongkot J, Ambroggio X, Duffy PE, Wu Y, Narum DL.
    J Biol Chem; 2016 Sep 16; 291(38):19913-22. PubMed ID: 27432885
    [Abstract] [Full Text] [Related]

  • 20. A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults.
    Sklar MJ, Maiolatesi S, Patterson N, Sedegah M, Limbach K, Teneza-Mora N, Chuang I, Hollis-Perry KM, Banania JG, Guzman I, Ganeshan H, Reyes S, Hollingdale MR, Wong M, Lindstrom A, Reyes A, Alcorta Y, Garver L, Bankard K, Belmonte A, Belmonte M, Huang J, Gowda K, Inoue S, Velasco R, Bergmann-Leitner E, Hutter J, Lee T, Adams N, Chaudhury S, Hunt D, Tamminga C, Berrie E, Bellamy D, Bittaye M, Ewer K, Diggs C, Soisson LA, Lawrie A, Hill A, Richie TL, Villasante E, Epstein JE, Duplessis CA.
    PLoS One; 2021 Sep 16; 16(9):e0256980. PubMed ID: 34495988
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.